HUM August 2026 Options Begin Trading

Humana (HUM) is the subject of an options income idea: the $260 put is bid $31.80, implying a net cost basis of $228.20 if assigned (stock at $264.60), is ~2% OTM with a modeled 60% chance to expire worthless and a 12.23% cash-return (18.15% annualized) YieldBoost. On the call side, the $275 call is bid $33.20, ~4% OTM with a 45% probability to expire worthless; selling it as a covered call would yield a 12.55% premium boost (18.62% annualized) or a 16.48% total return if called at August 2026 expiration. Both option contracts show implied volatility around 46% versus a 12‑month realized volatility of ~44%; figures exclude broker commissions and dividends.

Analysis

Market structure: The option market is signaling yield-seeking demand into HUM: the Aug‑2026 260 put pays $31.80 (breakeven $228.20) and the 275 call pays $33.20 (boost ~12–12.6%, annualized ~18%). Winners are income/semi-passive buyers of HUM or option sellers who can deploy capital; losers are pure growth holders who cede upside above $275. Implied vol ~46% vs realized ~44% shows only a modest volatility risk premium, so premiums are attractive but not extreme.

Risk assessment: Tail risks center on Medicare Advantage (MA) policy shocks or large claims that could trigger >20% downside — a plausible single-event tail given HUM’s MA exposure. Immediate risk (days) is IV and earnings-driven repricing; short-term (weeks–months) is CMS rate decisions and enrollment updates; long-term (quarters–years) is structural MA margin pressure or provider cost inflation. Hidden dependency: capitation contracts and risk-adjustment rules; a single regulatory tweak can nonlinearly compress earnings.

Trade implications: Direct plays that fit risk budgets are cash‑secured put selling (collect high carry) or buy‑write to harvest YieldBoost, with strict assignment controls. Given modest IV premium, prefer defined‑risk structures (put spreads, buy‑writes) over naked short vega. Cross‑asset: a regulatory shock would tighten credit spreads for HUM and widen insurer CDS; hedge with corporate protection if leveraged.

Contrarian angles: The retail-friendly headline “60% chance put expires worthless” understates tail regulatory risk — downside may be underpriced by ~10–15% in stressed scenarios. Historical parallel: 2017–2018 MA adjustments produced rapid reratings; option sellers would have been assigned into steep drawdowns. Unintended consequence: being forced to hold at $228 in a prolonged MA margin compression scenario ties capital and creates opportunity cost.

Key Decisions for Investors

• Establish a small, cash‑secured short position: sell-to-open HUM Aug‑2026 260 puts sized to 1–2% of portfolio notional (max cash commitment $26k per 100‑share lot). Rationale: collect $31.80 for breakeven $228.20; exit/roll if HUM < $230 or if IV spikes above 60% or delta <-0.45.
• If willing to own equity, initiate a buy-write: buy HUM up to 2–3% position at or below $265 and sell Aug‑2026 275 calls for $33.20. Target return: ~16.5% if called; close the call if stock > $285 or following a negative earnings/CMS update.
• If concerned about regulatory tail risk, use defined‑risk protection: convert the put into a 260/245 put spread (sell 260, buy 245, Aug‑2026) sized to 1–2% to cap downside to the 15‑point width minus net credit. Implement if net debit < $8/share to keep max loss ~<$7/share.
• Hedge portfolio regulatory exposure: buy short-dated HUM or insurer downside protection (e.g., purchase HUM or insurer 30–120 day puts) ahead of CMS rate announcements; if CMS reduces MA rates by >2% relative to consensus, reduce insurer exposure by 50% within 5 trading days.